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Summary  In  Minas  Gerais,  Brazil,  almost  500,000  dengue  fever  cases  were
reported  to  the  State  Surveillance  System  between  November  2012  and  July  2013.  An
analysis  of  the  laboratory-conﬁrmed  cases  revealed  a  higher  age-speciﬁc  incidence
in  adults  and  a  higher  case  fatality  rate  in  people  aged  ≥50.  Dengue  virus  serotypesDengue  serotype  4;
Epidemiology
1  and  4  (the  latter  of  which  is  an  emerging  serotype  in  Brazil)  were  responsible  for
the  outbreak.
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inas  Gerais  is  one  of  26  Brazilian  states;  it  is
ocated  in  southeast  Brazil  and,  with  19,597,330
nhabitants, is  the  second  most  populous  state.
n addition,  Minas  Gerais  has  the  fourth  largest
rea (586,528  km2)  in  the  country  [1].  The  dengue
irus was  ﬁrst  described  in  Minas  Gerais  in  1987,
nces. Published by Elsevier Ltd. All rights reserved.
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oFigure  1  The  number  of  reported  and  laboratory-conﬁ
2009  to  2013.
and  since  1996,  regular  outbreaks  have  caused
considerable illness  in  the  state.  The  disease  in
Minas Gerais  has  shown  marked  seasonality,  with
increases  in  the  number  of  reported  cases  occur-
ring during  November  and  December  and  peaking
in March  and  April  (Fig.  1).  Prior  to  2011,  two
major outbreaks  occurred;  approximately  147,000
cases were  reported  in  1998,  and  269,000  cases
were reported  in  2010.  Between  1987  and  2010,
only three  dengue  virus  serotypes  were  reported
to be  in  circulation  (DENV-1,  DENV-2,  and  DENV-3).
DENV-1  was  associated  with  both  previous  epidemic
years.  DENV-4  was  ﬁrst  detected  in  Brazil  in  1981
[2];  however,  this  serotype  was  not  reported  again
in Brazilian  territory  until  2010  [3]. In  May  2011,
DENV-4  was  identiﬁed  in  Minas  Gerais  for  the  ﬁrst
time. Although  only  one  case  caused  by  DENV-4  was
identiﬁed  that  year,  in  the  ﬁrst  half  of  2012,  15.8%
of all  isolates  were  typed  as  DENV-4.  DENV-1  con-
tinued  to  be  the  most  frequent  serotype  observed
in 2011  and  2012.  At  the  end  of  2012,  an  impor-
tant increase  in  the  incidence  was  detected  by  the
state surveillance  system,  marking  the  largest  ever
dengue outbreak  in  Minas  Gerais.  The  purpose  of
this study  was  to  describe  this  dengue  outbreak,
with an  emphasis  on  the  emergence  of  DENV-4.
Materials and methods
Dengue  is  a  reportable  disease  in  Brazil.  Health
professionals report  dengue  cases  to  local  health
departments using  a  standardized  form.  Deaths
are investigated  with  a  more  extensive  standard-
ized form,  focusing  on  comorbid  conditions  and
risk factors.  All  reported  cases  are  registered  in
C
a
c
M dengue  cases  in  Minas  Gerais,  Brazil,  by  month,  from
he  National  Notiﬁable  Diseases  Surveillance  Sys-
em (SINAN).  Laboratory  conﬁrmation  of  cases
s based  on  serologic  tests  (IgM  enzyme-linked
mmunosorbent  assay  [ELISA]),  virus  isolation,  real-
ime polymerase  chain  reaction  (PCR),  or  NS1
ntigen  detection.  Immunohistochemical  studies
ere performed  on  samples  from  patients  who
ied from  dengue.  The  State  Laboratory  of  Pub-
ic Health  (Fundac¸ão  Ezequiel  Dias,  Minas  Gerais,
razil) performed  IgM  ELISA  using  the  Panbio,  Bris-
ane, Australia  and  IgM-capture  immunoenzymatic
echnique  (MAC-ELISA)  developed  by  Kuno  et  al.  [4]
or  the  detection  of  IgM  antibodies.  For  NS1  detec-
ion, the  Platelia  dengue  NS1  Ag  assay  (Bio-Rad)
as employed.  DENV  were  isolated  on  C3/36  cells
nd the  virus  serotype  was  identiﬁed  by  an  immu-
oﬂuorescence assay  using  monoclonal  antibodies
s described  by  Gubler  et  al.  [5]. PCR  were  per-
ormed using  RT-PCR  with  primers  and  methodology
escribed previously  by  Lanciotti  et  al.  [6].  The
razilian  Ministry  of  Health  and  the  Minas  Gerais
ealth Secretary  recommend  testing  all  suspected
ases  of  severe  dengue  and  cases  with  dengue
arning signs,  regardless  of  whether  there  is an
utbreak  [7,8].
We  evaluated  surveillance  data  for  all  reported
ase-patients for  whom  symptom  onset  occurred
rom November  1,  2012  to  July  31,  2013.
e described  the  demographic  characteristics  of
aboratory-conﬁrmed  cases,  and  we  also  calculated
he age-speciﬁc  incidence  and  the  relative  risk
f death  by  age  group.  STATA  version  11.0  (Stata
orp., College  Station,  TX,  USA)  was  used  for  data
nalyses.  This  study  was  approved  by  the  Ethi-
al Review  Committee  of  the  Federal  University  of
inas Gerais,  Brazil  (no.  16718113.2.0000.5149).
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sigure  2  The  incidence  of  reported  dengue  cases  per  100
o  July  2013.
esults
uring  the  period  analyzed,  499,264  cases  of
engue  were  reported  statewide,  conﬁrming  a
ajor epidemic  (Fig.  1)  and  one  of  the  largest  epi-
emics  worldwide.  The  overall  incidence  for  the
tate was  2514  reported  case-patients  per  100,000
eople;  the  incidence  peaked  during  March  and
pril (Fig.  1).  A  total  of  788  of  the  853  (92.4%)
unicipalities reported  dengue  cases,  and  485
unicipalities  had  incidences  of  ≥300  reported
ases per  100,000  people  (Fig.  2).
The  predominant  serotypes  circulating  during
he current  epidemic  are  DENV-4  and  DENV-1.  Of  the
53 Minas  Gerais  municipalities,  serotyping  surveil-
ance was  performed  in  57  (6.7%).  DENV-4  was
solated in  samples  from  41  (71.9%)  municipalities,
hile DENV-1  was  circulating  in  35  (61.4%)  munic-
palities. Nineteen  (17.5%)  municipalities  reported
oth serotypes.  Of  the  samples  from  469  patients
ho tested  positive  by  PCR  or  virus  isolation;  224
47.8%) were  positive  for  DENV-4  and  245  (52.2%)
or DENV-1.
The incidence  and  case  fatality  rates  were
ssociated with  age.  The  risk  of  dengue  among
ase-patients aged  30—64  (age-speciﬁc  incidence
pproximately  670  per  100,000)  was  2.1  times
igher than  the  risk  for  case-patients  aged  0—14
t
M
m population  in  Minas  Gerais,  Brazil,  from  November  2012
age-speciﬁc  incidence  approximately  315.6  per
00,000)  (Table  1).  There  were  a total  of  96
aboratory-conﬁrmed  deaths  due  to  dengue.  Of  the
ight case-patients  for  whom  it  was  possible  to
eﬁne the  serotype,  DENV-4  was  identiﬁed  in  six
75%) and  DENV-1  in  two  (25%).  The  mean  age
f the  96  case-patients  who  died  was  52.2  years
range  5—96  years),  and  58  case-patients  (60.4%)
ere ≥50  years  (Table  1). Of  the  case-patients  who
ied, 58.3%  had  histories  of  comorbid  conditions
Table  2).  As  expected,  the  frequency  of  comorbidi-
ies increased  in  the  older  age  groups  (2 for  linear
rend: 16.3,  p  =  0.000).  The  median  time  from  the
ate of  symptom  onset  to  the  date  of  death  was  7
ays. The  risk  of  death  was  higher  in  case-patients
ged ≥50  years.  The  elderly  (≥65  years  of age)  had
n approximately  11.2  times  higher  risk  of  death
han the  0—14  age  group  (Table  1).
onclusions
rom  2012  to  2013,  the  combination  of  an  emergent
erotype (DENV-4)  and  a  highly  susceptible  popula-
ion created  the  most  severe  epidemic  observed  in
inas Gerais  State,  Brazil.
The incidence  was  highest  among  young  and
iddle-aged adults.  The  lower  incidence  observed
550  F.F.  Amâncio  et  al.
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Table  2  History  of  comorbid  conditions  among  case-
patients  who  died  of  dengue,  Minas  Gerais,  November
2012—July  2013.
Comorbid  conditions  n (%)
History  of  comorbid  conditions  56  (58.3)
Hypertension  12  (12.5)
Hypertension  with  COPD  and
cardiac  disease
2 (2.1)
Hypertension  with  obesity 1  (1.1)
Hypertension  with  diabetes
mellitus
3  (3.1)
Diabetes  mellitus  1  (1.1)
Diabetes  mellitus  and  previous
stroke
1 (1.1)
Diabetes  mellitus  with  COPD  1  (1.1)
Diabetes  mellitus  with
hypertension  and  renal  chronic
disease
1 (1.1)
Cardiac  disease  and  hypertension  4  (4.2)
Cardiac  disease  (cardiomyopathy,
coronary  artery  disease,  or
valvular  heart  disease)
2 (2.1)
Cardiac  disease  and  previous  stroke 1  (1.1)
Chronic  pulmonary  disease  (COPD,
pulmonary  hypertension,  asthma)
3 (3.1)
Chronic  renal  disease 3  (3.1)
Hypothyroidism  3  (3.1)
Lupus  erythematosus  3  (3.1)
Alzheimer  disease  2  (2.1)
Epilepsy  1  (1.1)
Biliary  disease  1  (1.1)
Cirrhosis  1  (1.1)
Immune  thrombocytopenia  1  (1.1)
Leukemia  1  (1.1)
Major  Depression  1  (1.1)
Peptic  ulcer  1  (1.1)
Pregnancy  1  (1.1)
Renal  cancer  1  (1.1)
Rheumatoid  arthritis  1  (1.1)
Sickle-cell  disease  1  (1.1)
Thyroid  cancer  1  (1.1)
Vascular  disease,  severe  1  (1.1)
No  history  of  comorbid  conditions  40  (41.7)
Total  96  (100)
i
t
a
t
f
c
g
I
d
t
dCOPD, chronic obstructive pulmonary disease.
n  case-patients  aged  0—14  and  ≥65  can  be  par-
ially explained  by  nonspeciﬁc  symptoms  in  these
ge groups.  Whereas  primary  and  secondary  infec-
ions in  adults  are  more  symptomatic  and  more
requently  present  as  classical  dengue  fever,  in
hildren,  a primary  infection  by  any  serotype  is
enerally  unapparent  or  causes  mild  disease  [9].
n elderly  patients,  fever,  a  criterion  for  dengue
iagnosis, may  be  absent  in  9%  of  the  popula-
ion (≥65  years  of age)  with  dengue.  Other  typical
engue  clinical  presentations  (rashes,  bone  pain,
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[engue  virus  serotype  4  in  a  highly  susceptible  pop
nd  abdominal  pain)  are  also  less  frequent  in  the
lderly  [10].
Despite  the  higher  proportion  of  cases  among
ase-patients aged  15—49,  the  highest  case  fatality
ates  occurred  among  those  ≥50  years  of  age,  espe-
ially in  case-patients  aged  ≥65.  We  believe  that
he increased  risk  of  death  in  this  group  is  caused
y the  difﬁculty  in  managing  dengue  in  a  population
ith a  high  frequency  of  comorbidities.  In  addi-
ion, in  areas  where  the  occurrence  of  dengue  is
elatively  recent,  as  in  Minas  Gerais  and  most  of
razil [11],  older  people  are  not  entirely  immune
nd carry  an  increased  risk  for  secondary  infection
12]  and,  consequently,  more  severe  disease.
Although  recent  studies  in  Brazil  have  shown  an
ncreasing  trend  in  the  number  of  severe  cases  in
hildren  [11,13]  that  conﬁrm  the  predictions  of
roximity  to  the  incidence  pattern  of  some  Asian
ountries [14—16],  these  studies  were  conducted
rior to  the  emergence  of  DENV-4.  It  is  possible
hat the  emergence  of  DENV-4  has  postponed  this
rend; this  argument  is supported  by  the  current
iral susceptibility  models  [17,18].
This  brief  report  demonstrates  that  over  a  period
f nearly  two  years,  the  introduction  of  a new
engue virus  serotype  (DENV-4)  in  a  region  with  a
igh mosquito  spread  and  high  human  susceptibility
as able  to  cause  a  large  outbreak  and  a  signiﬁcant
umber of  deaths.  Young  and  middle-aged  adults
ad a  high  incidence  of  dengue  fever;  however,
he elderly  had  the  highest  risk  of  death.  Our  data
aise the  following  important  issues:  (1)  consider-
ng  the  aging  population  in  Brazil,  similar  to  that  of
any developed  countries,  as  well  as  the  high  sus-
eptibility  to  emerging  serotypes  worldwide,  any
accine program  should  consider  targeting  older
ge groups;  (2)  as  the  clinical  management  of
engue  is  based  primarily  on  the  replacement  of
arge volumes  of  ﬂuids,  clinical  studies  should  inves-
igate whether  the  current  management  of  dengue
s appropriate  for  adults  and  the  elderly,  partic-
larly those  with  comorbid  conditions;  and  (3)
uidelines  should  emphasize  the  need  for  the  close
linical  monitoring  of  adults  and  elderly  patients
ith comorbidities,  as  they  are  at  increased  risk  of
eath.
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